Skip to main content
Advertisement

Main menu

  • Home
  • Content
    • Current Issue
    • Accepted Manuscripts
    • Article Preview
    • Past Issue Archive
    • AJNR Case Collection
    • Case of the Week Archive
    • Classic Case Archive
    • Case of the Month Archive
  • Special Collections
    • Spinal CSF Leak Articles (Jan 2020-June 2024)
    • 2024 AJNR Journal Awards
    • Most Impactful AJNR Articles
  • Multimedia
    • AJNR Podcast
    • AJNR Scantastics
    • Video Articles
  • For Authors
    • Submit a Manuscript
    • Author Policies
    • Fast publishing of Accepted Manuscripts
    • Graphical Abstract Preparation
    • Manuscript Submission Guidelines
    • Imaging Protocol Submission
    • Submit a Case for the Case Collection
  • About Us
    • About AJNR
    • Editorial Board
  • More
    • Become a Reviewer/Academy of Reviewers
    • Subscribers
    • Permissions
    • Alerts
    • Feedback
    • Advertisers
    • ASNR Home
  • Other Publications
    • ajnr

User menu

  • Alerts
  • Log in

Search

  • Advanced search
American Journal of Neuroradiology
American Journal of Neuroradiology

American Journal of Neuroradiology

ASHNR American Society of Functional Neuroradiology ASHNR American Society of Pediatric Neuroradiology ASSR
  • Alerts
  • Log in

Advanced Search

  • Home
  • Content
    • Current Issue
    • Accepted Manuscripts
    • Article Preview
    • Past Issue Archive
    • AJNR Case Collection
    • Case of the Week Archive
    • Classic Case Archive
    • Case of the Month Archive
  • Special Collections
    • Spinal CSF Leak Articles (Jan 2020-June 2024)
    • 2024 AJNR Journal Awards
    • Most Impactful AJNR Articles
  • Multimedia
    • AJNR Podcast
    • AJNR Scantastics
    • Video Articles
  • For Authors
    • Submit a Manuscript
    • Author Policies
    • Fast publishing of Accepted Manuscripts
    • Graphical Abstract Preparation
    • Manuscript Submission Guidelines
    • Imaging Protocol Submission
    • Submit a Case for the Case Collection
  • About Us
    • About AJNR
    • Editorial Board
  • More
    • Become a Reviewer/Academy of Reviewers
    • Subscribers
    • Permissions
    • Alerts
    • Feedback
    • Advertisers
    • ASNR Home
  • Follow AJNR on Twitter
  • Visit AJNR on Facebook
  • Follow AJNR on Instagram
  • Join AJNR on LinkedIn
  • RSS Feeds

Welcome to the new AJNR, Updated Hall of Fame, and more. Read the full announcements.


AJNR is seeking candidates for the position of Associate Section Editor, AJNR Case Collection. Read the full announcement.

 

Research ArticleAdult Brain

Presurgical Identification of Primary Central Nervous System Lymphoma with Normalized Time-Intensity Curve: A Pilot Study of a New Method to Analyze DSC-PWI

A. Pons-Escoda, A. Garcia-Ruiz, P. Naval-Baudin, M. Cos, N. Vidal, G. Plans, J. Bruna, R. Perez-Lopez and C. Majos
American Journal of Neuroradiology October 2020, 41 (10) 1816-1824; DOI: https://doi.org/10.3174/ajnr.A6761
A. Pons-Escoda
aRadiology Department (A.P.-E., P.N.-B., M.C., C.M.), Institut de Diagnòstic per la Imatge, Hospital Universitari de Bellvitge. L’Hospitalet de Llobregat, Barcelona, Spain
fNeurooncology Unit (A.P.-E., N.V., G.P., J.B., C.M.), Insitut Català d’Oncologia, Institut d’Investigació Biomèdica de Bellvitge, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for A. Pons-Escoda
A. Garcia-Ruiz
bRadiomics Group (A.G.-R., R.P.-L.), Vall d’Hebron Institut d’Oncologia, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for A. Garcia-Ruiz
P. Naval-Baudin
aRadiology Department (A.P.-E., P.N.-B., M.C., C.M.), Institut de Diagnòstic per la Imatge, Hospital Universitari de Bellvitge. L’Hospitalet de Llobregat, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for P. Naval-Baudin
M. Cos
aRadiology Department (A.P.-E., P.N.-B., M.C., C.M.), Institut de Diagnòstic per la Imatge, Hospital Universitari de Bellvitge. L’Hospitalet de Llobregat, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for M. Cos
N. Vidal
cPathology Department (N.V.), Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain
fNeurooncology Unit (A.P.-E., N.V., G.P., J.B., C.M.), Insitut Català d’Oncologia, Institut d’Investigació Biomèdica de Bellvitge, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for N. Vidal
G. Plans
dNeurosurgery Department (G.P.), Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain
fNeurooncology Unit (A.P.-E., N.V., G.P., J.B., C.M.), Insitut Català d’Oncologia, Institut d’Investigació Biomèdica de Bellvitge, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for G. Plans
J. Bruna
eNeurology Department (J.B.), Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain
fNeurooncology Unit (A.P.-E., N.V., G.P., J.B., C.M.), Insitut Català d’Oncologia, Institut d’Investigació Biomèdica de Bellvitge, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for J. Bruna
R. Perez-Lopez
bRadiomics Group (A.G.-R., R.P.-L.), Vall d’Hebron Institut d’Oncologia, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for R. Perez-Lopez
C. Majos
aRadiology Department (A.P.-E., P.N.-B., M.C., C.M.), Institut de Diagnòstic per la Imatge, Hospital Universitari de Bellvitge. L’Hospitalet de Llobregat, Barcelona, Spain
fNeurooncology Unit (A.P.-E., N.V., G.P., J.B., C.M.), Insitut Català d’Oncologia, Institut d’Investigació Biomèdica de Bellvitge, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for C. Majos
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • Responses
  • References
  • PDF
Loading

Abstract

BACKGROUND AND PURPOSE: DSC-PWI has demonstrated promising results in the presurgical diagnosis of brain tumors. While most studies analyze specific parameters derived from time-intensity curves, very few have directly analyzed the whole curves. The aims of this study were the following: 1) to design a new method of postprocessing time-intensity curves, which renders normalized curves, and 2) to test its feasibility and performance on the diagnosis of primary central nervous system lymphoma.

MATERIALS AND METHODS: Diagnostic MR imaging of patients with histologically confirmed primary central nervous system lymphoma were retrospectively reviewed. Correlative cases of glioblastoma, anaplastic astrocytoma, metastasis, and meningioma, matched by date and number, were retrieved for comparison. Time-intensity curves of enhancing tumor and normal-appearing white matter were obtained for each case. Enhancing tumor curves were normalized relative to normal-appearing white matter. We performed pair-wise comparisons for primary central nervous system lymphoma against the other tumor type. The best discriminatory time points of the curves were obtained through a stepwise selection. Logistic binary regression was applied to obtain prediction models. The generated algorithms were applied in a test subset.

RESULTS: A total of 233 patients were included in the study: 47 primary central nervous system lymphomas, 48 glioblastomas, 39 anaplastic astrocytomas, 49 metastases, and 50 meningiomas. The classifiers satisfactorily performed all bilateral comparisons in the test subset (primary central nervous system lymphoma versus glioblastoma, area under the curve = 0.96 and accuracy = 93%; versus anaplastic astrocytoma, 0.83 and 71%; versus metastases, 0.95 and 93%; versus meningioma, 0.93 and 96%).

CONCLUSIONS: The proposed method for DSC-PWI time-intensity curve normalization renders comparable curves beyond technical and patient variability. Normalized time-intensity curves performed satisfactorily for the presurgical identification of primary central nervous system lymphoma.

ABBREVIATIONS:

AUC
area under the curve
NAWM
normal-appearing white matter
nTIC
normalized time-intensity curve
MSID
maximal signal intensity drop
PCNSL
primary central nervous system lymphoma
PSR
percentage of signal recovery
TIC
time-intensity curve
CE-T1WI
contrast-enhanced T1WI
TTA
time-to-arrival
rCBV
relative cerebral blood volume

The presurgical diagnosis of brain tumors is highly relevant to patient management. Although histopathology remains the criterion standard, a presurgical suggestion of particular tumor types, such as primary central nervous system lymphoma (PCNSL) or metastasis, may greatly influence further procedures.1⇓⇓-4

MR imaging plays a pivotal role in the presurgical identification of brain tumors. Conventional MR imaging findings have been widely described; nevertheless, their performance is limited.5⇓⇓⇓⇓⇓-11 Given this limitation, an increasing number of studies have focused on monitoring physiologic and metabolic characteristics. In this sense, parameters derived from DSC-PWI have shown promising results in the diagnosis of brain tumors, and especially PCNSL.12⇓⇓⇓⇓⇓⇓⇓-20 DSC-PWI generates time-intensity curves (TICs) from dynamic monitoring of T2* signal intensity changes during contrast administration. Specific well-known parameters such as relative cerebral blood volume (rCBV) and percentage of signal recovery (PSR) are extracted from these TICs. Although visual evaluation of the entire TICs has been suggested by some authors,21 to the best of our knowledge, there are no previous studies that have quantitatively evaluated the whole range of points that form the TIC altogether. This is probably because technical variability and patient physiologic characteristics hinder direct point-by-point comparisons.22⇓-24

Constructing normalized TICs (nTICs) would minimize the influence of physiologic and some technical parameters (especially regarding the timing of dynamics) on the TIC, offering interesting advantages: 1) It enables the possibility of performing a direct comparison of the entire nTIC between tumor types on a point-by-point basis, not limited to concrete parameters such as rCBV or PSR; and 2) it enhances the construction of user-friendly classifiers based on quantitative and visual comparison of particular cases to a data set of brain tumors.

The present article has 2 aims: first, to design an applicable method of processing TICs from DSC-PWI that allows obtaining normalized and comparable curves beyond technical and patient variability; and second, to test the applicability of this method by evaluating its diagnostic performance in a large series of patients with PCNSL.

MATERIALS AND METHODS

This article has been revised for publication by the research ethics committee of our tertiary hospital (Hospital Universitari de Bellvitge). The patient data were anonymized for this analysis. The confidential information of the patients was protected in accordance with national and European norms. Unspecific informed consent to participate in research projects was obtained from all patients. A waiver of a specific informed consent was provided by the ethics committee for this retrospective study.

Patients

Newly diagnosed patients with histologically confirmed PCNSL (2006–2019) were retrieved from our center database. Correlative cases by date and number, of glioblastoma, anaplastic astrocytoma, metastasis, and meningioma were retrieved from the same database for comparison.

Patients without PCNSL were selected to achieve the same number of patients with PCNSL, matched by year of acquisition. The rationale was to equalize the influence of technical differences of MR imaging sequences during such a long period (2006–2019) among tumor types. Inclusion criteria for the study were as follows: 1) confirmed tumor diagnosis by histology according to The World Health Organization 2007 or 2016 criteria, 2) an available diagnostic MR imaging examination including DSC-PWI and axial contrast-enhanced T1WI (CE-T1WI), 3) absence of previous oncospecific treatment at the time of the MR imaging examination, and 4) enhancing tumor on CE-T1WI with a shortest diameter of at least 10 mm. The flow diagram of study participants is shown in the On-line Figure.

Imaging

All the MR imaging examinations included in the study were acquired in the same tertiary hospital with 1 of 3 different scanners: Ingenia 3T with a 32-channel head coil, Ingenia or Intera 1.5T with a 16-channel head coil (Philips Healthcare). Acquisition parameters for DSC-PWI sequences (all gradient-echo) are summarized in On-line Tables 1 and 2. The intravenous contrast (gadobutrol; 1 mmol/mL, 0.1 mmol/kg) injection protocol was as follows: 18- or 20-ga peripheral intravenous access. No preload was performed. Baseline acquisition was on the order of 10 points. The start of the automatic injection (power injector at 4–5 mL/s) was by a manual setting. A final bolus of saline (25–50 mL) was injected at the same speed. The time and number of dynamics ranged from 1.26 to 3.55 seconds and 30 to 60, respectively.

View this table:
  • View inline
  • View popup

Summary of the results in training and test subsets

The quality of the sequences was evaluated by visual inspection by 2 neuroradiologists (A.P.-E. and C.M.) with 5 years of experience in MR imaging of brain tumors. The examinations were labeled as poor quality and excluded from the study under the following circumstances: 1) artifacts prevented enhancing tumor segmentation on CE-T1WI or coregistration of CE-T1WI and DSC-PWI, or 2) an obvious low signal-to-noise ratio was observed in the raw TICs.

Postprocessing

Supervised semiautomatic volumetric segmentations (histogram thresholding and morphologic operations) of the enhancing tumor and normal-appearing white matter (NAWM) were performed on CE-T1WI and coregistered with DSC-PWI. Necrosis and nonenhancing components of the tumors were excluded from the segmentation. Semiautomatic volumetric segmentation of the whole enhancing lesion instead of partial, manual, or single-section ROI selection methods was chosen to minimize operator-dependency as well as to include all the intrinsic heterogeneity of the tumors in the analysis. 3D Slicer, Version 4.10 (http://www.slicer.org) was used for segmentation,25 and the BRAINSFit module of 3D Slicer, for coregistering.26

Two TICs for each case, 1 of the enhancing tumor and 1 of the NAWM, were obtained by averaging the TICs for all voxels within the segmented area. Baseline and the initial point of the descending curve were aligned. Signal intensity values (SIi) of the enhancing tumor TIC were normalized by dividing by the maximal signal intensity drop (MSID) of the NAWM (SIi/MSIDNAWM). Time values (Ti) were normalized as relative to the period of the descending curve on NAWM, which is the subtraction of time-to-peak (TTP) minus time-to-arrival (TTA) [Ti / (TTPNAWM – TTANAWM)]. We used TTP-TTA instead of TTP to normalize time values to avoid the potential human operator variability of TTA, mainly due to differences in the coordination between contrast infusion and sequence start. Finally, the same constant time points (0.2 TTP-TTA fractions from 0 to a total of 5, resulting in 26 constant time points) were extrapolated for all the curves (Fig 1). To detect the initial point of the descending curve necessary for alignment and TTA calculation, we calculated the average slope and SD of the 4 points before and after the MSID, and the first point where the curve slope became greater than the average minus the SD was established as the initial descending point.

FIG 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIG 1.

Solid (A and B) and necrotic (D and E) tumors and respective NAWM segmentations on axial CE-T1WI (A and D) and coregistered on DSC-PWI (B and E). Resultant raw curves by averaging the TIC for each voxel within the segmented areas (C and F), noncomparable due to differences in time, intensity, baseline, or initial point of the descending curve. Exemplification of the parameters used to normalize the curves, MSID, and TTP-TTA, relative to NAWM (G). Resultant normalized tumor curves, superimposable and comparable point by point (H). Curves with the exact same number of time-matching points and sharing common units of time (relative to TTP-TTA of the NAWM) and intensity (relative to MSID of the NAWM).

The TICs were processed using Python 3.6 software (https://www.python.org/downloads/release/python-360/).

As a secondary subanalysis, to compare our method with conventional rCBV and PSR measures, we obtained mean rCBV and PSR values. rCBV was obtained with leakage correction27 and normalized to the NAWM; PSR was obtained as described by Cha et al.28 Both parameters were calculated using the same volumetric segmentation and coregistration as in the main analysis.

Statistics

The study sample was split into training (70%) and test (30%) subsets, which were balanced by the date of examination to minimize the impact of quality and technical differences between TICs of the more distant-in-time examinations. For the statistical analysis, pair-wise comparisons between PCNSL and each of the other tumor types were made. First, a stepwise selection was run in the training set, which rendered the 5 best discriminatory points per comparison pair. Stepwise selection is an unsupervised automatic procedure for variable selection, which can be used in cases of a large number of potential explanatory variables but with no underlying theory on which to base the model. Subsequently, predictive models were trained using logistic binary regression in each pair of the training set. Finally, the constructed classifiers based on the algorithms from the training set were applied to the test set.

All the statistical computations were performed with R statistical and computing software, Version 3.5.1 (http://www.r-project.org).29

RESULTS

Patients

Fifty PCNSLs fulfilled the inclusion criteria and were included in the study. An additional 50 glioblastomas, 45 anaplastic astrocytomas, 50 metastases, and 50 meningiomas balanced with PCNSLs by date were included for comparison. The entire initial dataset included 245 patients (133 men; mean age, 59 years; range, 18–85 years). Demographics of the study sample are summarized in On-line Table 3.

Anaplastic astrocytoma was the only tumor type whose number of cases could not match the total of PCNSLs. Although the prevalence of anaplastic astrocytoma was higher than that of PCNSL, this was because only 45 cases fulfilled inclusion criterion number 4, “Enhancing tumor on CE-T1WI with a shortest diameter of at least 10 mm.”

A total of 3 PCNSLs, 2 glioblastomas, 6 anaplastic astrocytomas, and 1 metastasis were ruled out by the quality filter. As a result, 47 PCNSLs, 48 glioblastomas, 39 anaplastic astrocytomas, 49 metastases, and 50 meningiomas were included in the final dataset (total n = 233). The patient dataset was split into training (70%) and test (30%) subsets balanced by the date of examination (training: 33 PCNSLs, 35 glioblastomas, 29 anaplastic astrocytomas, 36 metastases, and 36 meningiomas; test: 14 PCNSLs, 13 glioblastomas, 10 anaplastic astrocytomas, 13 metastases, and 14 meningiomas) (On-line Figure).

Normalized Curve Analysis and Pair-Wise Comparisons with PCNSL

Mean nTICs obtained from the training subset for each tumor type are shown in Fig 2. These mean curves are superimposable and comparable in a single graph due to the applied normalization method. This format provides a user-friendly tool for visual comparisons of nTICs. In this sense, notable differences were found between tumor-type nTICs on a first visual assessment, the most obvious around the MSID and the signal recovery segments. It is remarkable that all the curves in Fig 2 have the same number of time-matching points as well as sharing common units of time (relative to TTP-TTA of the NAWM) and intensity (relative to MSID of the NAWM). These features enable point-by-point absolute quantification of differences.

FIG 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIG 2.

Normalized mean tumor curves for each type (PCNSL, glioblastoma, anaplastic astrocytoma, metastasis, and meningioma) obtained in the training subset (A). The curves are superimposable and comparable in a single graphic. This format provides a user-friendly tool for visual comparison of curves. Paired comparisons of normalized mean tumor curves for PCNSL against glioblastoma (B), anaplastic astrocytoma (C), metastasis (D), and meningioma (E), as well as representation of the 5 stepwise selected discriminatory TTP-TTA time points per pair (black dots).

The 5 best discriminatory time points per pair of tumors achieved by stepwise selection are represented in Fig 2. The classifier algorithms, based on the logistic binary regression with the intercept and the relative power (coefficient) for each stepwise selected time point, are shown in On-line Tables 4 and 5.

Satisfactory results were obtained to enable segregating tumor types in all pair-wise comparisons in the training set. In summary, the area under the curve (AUC) values for all bilateral comparisons ranged between 0.86 (PCNSL versus anaplastic astrocytoma) and 1.00 (PCNSL versus meningioma), while the classification accuracies ranged between 74% (PCNSL versus anaplastic astrocytoma) and 97% (PCNSL versus meningioma). The same algorithms were applied to the test subset of tumors, confirming satisfactory classifications with AUC values between 0.83 (PCNSL versus anaplastic astrocytoma) and 0.96 (PCNSL versus glioblastoma) and accuracies between 71% (PCNSL versus anaplastic astrocytoma) and 96% (PCNSL versus meningioma) (Table).

The discriminating threshold of the constructed predictive model was set to zero to calculate the exposed results. Zero value corresponds to the point of maximum accuracy in binary logistic regressions. Nevertheless, this threshold can be easily modified, allowing the algorithm to be adapted to different clinical scenarios requiring specific sensitivity or specificity profiles.

Figures 3 and 4 are real clinical examples of the classifier user-friendly applicability. The nTIC curves of particular “problem” cases are overlapped on mean nTIC curves of each tumor type to visually assess similarities. The values after running the algorithm on the “problem” cases are depicted in a scatterplot to visually assess the likelihood of a particular diagnosis.

FIG 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIG 3.

Example of clinical applicability on a “real” problem case. Axial CE-T1WI of 2 different patients (A and D) depicting 2 subcortical right frontal, solid enhancing tumors. PCNSL and anaplastic astrocytoma may be diagnostic possibilities to consider. Tumor normalized curves of each case overlapped to PCNSL, and anaplastic astrocytoma mean curves for visual assessment (B and E) show that the case in the upper row has similarities with PCNSL while in contrast, the case in the lower row has similarities with anaplastic astrocytoma. Representation of the classifier results on a scatterplot (C and F) demonstrates that the case in the upper row remains on the inferior side and may likely be a PCNSL, while the case in the lower row is more likely to be an anaplastic astrocytoma. We pathologically confirmed both diagnoses: case in the upper row, PCNSL; case in the lower row, anaplastic astrocytoma.

FIG 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIG 4.

Example of clinical applicability on a “real” problem case. Axial CE-T1WI of 2 different patients with similar tumors (A and D): well defined, solid, avidly enhancing and right frontal peripherally located. PCNSL and meningioma were the 2 main diagnostic options considered. The tumor normalized curve of each case overlapping with PCNSL and meningioma mean curves (B and E) show that the case in the upper row is similar to PCNSL while the case in the lower row is close to meningioma. Representation of the classifier results on the scatterplot (C and F) suggests that the cases are likely to be PCNSL and meningioma, respectively. We pathologically confirmed both diagnoses: case in the upper row, PCNSL, case in the lower row, meningioma.

Regarding the rCBV and PSR subanalyses, the performance of these parameters is summarized in On-line Tables 6 and 7. In a general sense, mean rCBV and PSR showed inferior diagnostic performance to nTICs, with the only accuracies being slightly superior for PSR in PCNSL versus anaplastic astrocytoma and PCNSL versus metastasis in the test subgroups.

DISCUSSION

In this study, we have reported the design of an innovative method to obtain normalized TICs from DSC-PWI beyond patient and technical differences, which allows the following: 1) constructing mean curves for visual analysis, 2) performing point-by-point statistical comparisons between curves, and 3) building classifiers. We have tested its applicability in the presurgical identification of PCNSL and obtained satisfactory results.

DSC-PWI is an MR imaging technique that can be performed on most MR imaging units currently and provides noninvasive in vivo assessment of microvascular systems. It consists of a dynamic temporal acquisition during the vascular first pass of a contrast bolus. The injection of gadolinium results in an initial reduction in T2 signal intensity of tissues and subsequent signal recovery during contrast washout. TICs can be generated from this process. Well-studied parameters such as rCBV and PSR are extracted from these curves. The rCBV corresponds to the AUC, is usually measured relative to the NAWM, and has been related to histologic measurements of tumor vascularization.22,24,30 The PSR is measured relative to the TIC baseline and may quantify the predominant T1 (signal recovery above baseline) or T2 (signal recovery below baseline) effects. These effects represent different leakage phenomena, which are explained by a complex combination of blood-brain barrier permeability, vascular volume fraction and vessel size, and tumor cell size and density.22,30,31 The extraction of rCBV or PSR from TICs may represent an oversimplification of the information contained in the entire TIC. In fact, the curves have many other points that remain excluded from these parameters. Along this line, some studies have suggested analyzing the whole curve to obtain improved information. Unfortunately, the proposed analysis was qualitative and limited to the visual pattern evaluation of the curve.21 Quantitative assessment of the entire curve has not been accomplished to date, to our knowledge. This could be due to differences in the acquisition technique (including operator-dependency on some parameters) and patient physiologic features, which produce noncomparable TICs between different examinations or patients.22,23 For example, there may be differences in the number and time of dynamics, in contrast injection start point and speed, or in patient heart rate preventing TICs from being comparable.16,22⇓-24

With these considerations in mind, we have developed a novel method for obtaining standardized, normalized, and comparable TICs independent of some technical and patient variability. We considered 2 parameters to be normalized to obtain comparable curves: time and intensity signal. Time was normalized as constant proportions of TTP-TTA from NAWM, and the time axis was re-dimensioned from seconds to fractions of 0.2 TTP-TTA units. Signal intensity was normalized to the MSID in NAWM. This normalization approach provided superimposable curves that could be visually analyzed and a list of point values that could be statistically compared among cases. Indeed, after normalization, mean curves for each tumor group could be constructed, allowing visual comparisons; the best discriminatory points with their optimal weighting for discrimination could be statistically determined, enabling the construction of classifiers; and particular cases could be displayed on scatterplots, providing visual representations of the likelihood of the diagnostic classification. Accordingly, we consider that this methodology could be further applied to construct user-friendly classifiers for the diagnosis of brain tumors. Examples of this potential application are shown in Figs 3 and 4.

We tested the performance of our method in the presurgical identification of PCNSL.

Reliable presurgical identification of PCNSL is vital because its management greatly differs from that of the other most prevalent enhancing brain tumors.1⇓-3,32 Maximal PCNSL resection is not recommended, and early stereotactic biopsy before corticosteroid administration is mandatory when it is suspected from imaging.32⇓⇓-35 Conventional MR imaging in PCNSL has been widely analyzed and may be useful for guiding initial management.5⇓-7 Nevertheless, these features may vary between patients and may overlap with other tumors.8⇓⇓-11 Thus, radiologic diagnosis of PCNSL remains a challenge, and additional advanced imaging techniques such as DSC-PWI are increasingly being evaluated. Many articles have evaluated the potential of DSC-PWI for differentiating PCNSL from other tumors with excellent results. These studies focus on rCBV and PSR quantifications. Basically, PCNSL shows low rCBV and high PSR.12⇓⇓⇓⇓⇓⇓⇓-20 Some authors recently reported an additional parameter directly extracted from TICs termed “peak height,” which has shown promising results.12,15 However, the lack of technique standardization, which causes variability in the identification of the best discriminating parameter and its relevant thresholds between different studies, as well as the lack of a user-friendly way to depict the results, impedes the widespread clinical application of these perfusion parameters.16,22⇓-24

We obtained satisfactory accuracy values in the comparisons between PCNSL and glioblastoma, anaplastic astrocytoma, metastasis, and meningioma in the test subset. Accuracies ranged between 71% (versus anaplastic astrocytoma) and 96% (versus meningioma). Moreover, the performance of the new method is overall superior compared with the analysis of conventional rCBV or PSR measures in our dataset (On-line Tables 6 and 7). Visual differences between the standardized nTICs of the different tumors were noted, especially in the segments around the MSID and the return to baseline (Fig 2). Statistical analysis confirmed that the best discriminatory points were situated around those segments of the curves that may somehow be related to the traditional rCBV, peak height, and PSR, which can be evaluated on conventional raw TICs. Indeed, we hypothesize that our method evaluates a mixture of these known relevant values along with other potentially discriminatory and otherwise hidden values of the curve, all together in a single step. Additionally, the method enables a user-friendly representation of the results (Figs 3 and 4). For this, we used a pair-wise model that takes advantage of the radiologist’s interaction by narrowing the most probable diagnoses. Then, the classifier is used as a support tool for diagnosis and not as an independent reader.

The variety of DSC pulse sequence parameters included in this retrospective study deserves special attention. Differences on these parameters (flip angle, TE, TR) affect the curve morphology and indeed seem to partially justify the variability in values and thresholds found in the literature regarding both rCBV and PSR.31 In this sense, an overall predominantly high T1-weighting of the sequences in our study (On-line Table 1) seems to be carrying higher PSR values if compared with some prior studies.20

Several limitations of our study must be considered. The single-site and retrospective character of the study may affect reproducibility. Nevertheless, the single-site origin may confer homogeneity that could be useful for this pilot study. At any rate, multicentric and prospective studies in new real clinical scenarios are needed for validation. The inclusion of a wide range of MR imaging examination dates and consequent technical differences may have affected the consistency of results. Some of them, such as the timing of dynamics or little heterogeneities in technical parameters, may be considered positive for the study by demonstrating the robustness of the method. Other parameters, such as variations in TE, TR, or flip angle, may be considered potentially confusing. In particular, higher T1-weighting of older sequences in our study may overestimate PSR values.20,31 Balancing of cases between tumor types and training and test cohorts was an attempt to minimize its impact on the results. Finally, we did not stratify subtypes of tumors or DSC sequence parameters used to avoid excessive fragmentation of the dataset.

On the other hand, our study has several strong points. First, a large sample of PCNSL was included, which provides a robust method and very high accuracy rates despite heterogeneity. Second, a wide-but-logical differential diagnosis was considered in the comparisons, which emphasizes the clinical usefulness of the results. Third, there is the semiautomatization of the image segmentation and coregistration as well as the TIC processing, which minimized operator-dependency in favor of reproducibility. Last, the method allowed including all the nTIC point values in the analysis without supervision, which provides an objective approach to the classification process.

CONCLUSIONS

The novel proposed method of assessing DSC-PWI renders normalized point-by-point comparable TICs beyond technique and patient variability, enables the construction of classifiers that can be presented in user-friendly interfaces, and shows good performance when tested, with excellent results in the presurgical identification of PCNSL.

Acknowledgments

We want to thank Marcel Vidal for assistance with statistics in an earlier version of the article.

Footnotes

  • Disclosures: Raquel Perez-Lopez—UNRELATED: Employment: Vall d’Hebron Institute of Oncology; Expert Testimony: Roche; Grants/Grants Pending: Astra Zeneca, CRIS Foundation, Prostate Cancer Foundation, FERO Foundation, Carlos III Research Institute*; Payment for Lectures Including Service on Speakers Bureaus: Roche. *Money paid to the institution.

References

  1. 1.↵
    1. Chiavazza C,
    2. Pellerino A,
    3. Ferrio F, et al
    . Primary CNS lymphomas: challenges in diagnosis and monitoring. Biomed Res Int 2018;2018:3606970 doi:10.1155/2018/3606970 pmid:30035121
    CrossRefPubMed
  2. 2.↵
    1. Altwairgi AK,
    2. Raja S,
    3. Manzoor M, et al
    . Management and treatment recommendations for World Health Organization grade III and IV gliomas. Int J Health Sci (Qassim) 2017;11:54–62 pmid:28936153
    PubMed
  3. 3.↵
    1. Enrique GV,
    2. Irving SR,
    3. Ricardo BI, et al
    . Diagnosis and management of brain metastases: an updated review from a radiation oncology perspective. J Cancer Metastasis Treat 2019;5:54 doi:10.20517/2394-4722.2019.20
    CrossRef
  4. 4.↵
    1. Euskirchen P,
    2. Peyre M
    . Management of meningioma. Presse Med 2018;47:e245–52 doi:10.1016/j.lpm.2018.05.016 pmid:30449639
    CrossRefPubMed
  5. 5.↵
    1. Tang YZ,
    2. Booth TC,
    3. Bhogal P, et al
    . Imaging of primary central nervous system lymphoma. Clin Radiol 2011;66:768–77 doi:10.1016/j.crad.2011.03.006 pmid:21513925
    CrossRefPubMed
  6. 6.↵
    1. Giannini C,
    2. Dogan A,
    3. Salomão DR
    . et al. CNS lymphoma. J Neuropathol Exp Neurol 2014;73:478–94 doi:10.1097/NEN.0000000000000076 pmid:24806301
    CrossRefPubMed
  7. 7.↵
    1. Bühring U,
    2. Herrlinger U,
    3. Krings T, et al
    . MRI features of primary central nervous system lymphomas at presentation. Neurology 2001;57:393–96 doi:10.1212/wnl.57.3.393 pmid:11515505
    Abstract/FREE Full Text
  8. 8.↵
    1. Upadhyay N,
    2. Waldman AD
    . Conventional MRI evaluation of gliomas. Br J Radiol 2011;84:84 Spec No 2(Spec Iss 2);S107–11 doi:10.1259/bjr/65711810
    CrossRef
  9. 9.↵
    1. Fink K,
    2. Fink J
    . Imaging of brain metastases. Surg Neurol Int 2013;4:209 doi:10.4103/2152-7806.111298
    CrossRef
  10. 10.↵
    1. Watts J,
    2. Box G,
    3. Galvin A, et al
    . Magnetic resonance imaging of meningiomas: a pictorial review. Insights Imaging 2014;5:113–22 doi:10.1007/s13244-013-0302-4 pmid:24399610
    CrossRefPubMed
  11. 11.↵
    1. Huang RY,
    2. Bi WL,
    3. Griffith B, et al
    ; International Consortium on Meningiomas. Imaging and diagnostic advances for intracranial meningiomas. Neuro Oncol 2019;21:i44–61 doi:10.1093/neuonc/noy143 pmid:30649491
    CrossRefPubMed
  12. 12.↵
    1. Lee MD,
    2. Baird GL,
    3. Bell LC, et al
    . Utility of percentage signal recovery and baseline signal in DSC-MRI optimized for relative CBV measurement for differentiating glioblastoma, lymphoma, metastasis, and meningioma. AJNR Am J Neuroradiol 2019;40:1145–50 doi:10.3174/ajnr.A6153 pmid:31371360
    CrossRefPubMed
  13. 13.↵
    1. Xing Z,
    2. You RX,
    3. Li J, et al
    . Differentiation of primary central nervous system lymphomas from high-grade gliomas by rCBV and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Clin Neuroradiol 2014;24:329–36 doi:10.1007/s00062-013-0255-5 pmid:23994941
    CrossRefPubMed
  14. 14.↵
    1. Liang R,
    2. Li M,
    3. Wang X, et al
    . Role of rCBV values derived from dynamic susceptibility contrast-enhanced magnetic resonance imaging in differentiating CNS lymphoma from high grade glioma: a meta-analysis. Int J Clin Exp Med 2014;7:5573–77 pmid:25664074
    PubMed
  15. 15.↵
    1. Neska-Matuszewska M,
    2. Bladowska J,
    3. Sąsiadek M, et al
    . Differentiation of glioblastoma multiforme, metastases and primary central nervous system lymphomas using multiparametric perfusion and diffusion MR imaging of a tumor core and a peritumoral zone: searching for a practical approach. PLoS One 2018;13:e0191341 doi:10.1371/journal.pone.0191341 pmid:29342201
    CrossRefPubMed
  16. 16.↵
    1. Xu W,
    2. Wang Q,
    3. Shao A, et al
    . The performance of MR perfusion-weighted imaging for the differentiation of high-grade glioma from primary central nervous system lymphoma: a systematic review and meta-analysis. PLoS One 2017;12:e0173430 doi:10.1371/journal.pone.0173430 pmid:28301491
    CrossRefPubMed
  17. 17.↵
    1. Wang S,
    2. Kim S,
    3. Chawla S, et al
    . Differentiation between glioblastomas, solitary brain metastases, and primary cerebral lymphomas using diffusion tensor and dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol 2011;32:507–14 doi:10.3174/ajnr.A2333 pmid:21330399
    Abstract/FREE Full Text
  18. 18.↵
    1. Lee IH,
    2. Kim ST,
    3. Kim HJ, et al
    . Analysis of perfusion weighted image of CNS lymphoma. Eur J Radiol 2010;76:48–51 doi:10.1016/j.ejrad.2009.05.013 pmid:19500931
    CrossRefPubMed
  19. 19.↵
    1. Calli C,
    2. Kitis O,
    3. Yunten N, et al
    . Perfusion and diffusion MR imaging in enhancing malignant cerebral tumors. Eur J Radiol 2006;58:394–403 doi:10.1016/j.ejrad.2005.12.032 pmid:16527438
    CrossRefPubMed
  20. 20.↵
    1. Mangla R,
    2. Kolar B,
    3. Zhu T, et al
    . Percentage signal recovery derived from MR dynamic susceptibility contrast imaging is useful to differentiate common enhancing malignant lesions of the brain. AJNR Am J Neuroradiol 2011;32:1004–10 doi:10.3174/ajnr.A2441 pmid:21511863
    Abstract/FREE Full Text
  21. 21.↵
    1. Chinchure S,
    2. Thomas B,
    3. Wangju S, et al
    . Mean intensity curve on dynamic contrast-enhanced susceptibility-weighted perfusion MR imaging: review of a new parameter to differentiate intracranial tumors. J Neuroradiol 2011;38:199–206 doi:10.1016/j.neurad.2011.07.002 pmid:21943571
    CrossRefPubMed
  22. 22.↵
    1. Welker K,
    2. Boxerman J,
    3. Kalnin A, et al
    ; American Society of Functional Neuroradiology MR Perfusion Standards and Practice Subcommittee of the ASFNR Clinical Practice Committee. ASFNR Recommendations for Clinical Performance of MR Dynamic Susceptibility Contrast Perfusion Imaging of the Brain. AJNR Am J Neuroradiol 2015;36:E41–51 doi:10.3174/ajnr.A4341 pmid:25907520
    Abstract/FREE Full Text
  23. 23.↵
    1. Willats L,
    2. Calamante F
    . The 39 steps: evading error and deciphering the secrets for accurate dynamic susceptibility contrast MRI. NMR Biomed 2013;26:913–31 doi:10.1002/nbm.2833 pmid:22782914
    CrossRefPubMed
  24. 24.↵
    1. Paulson ES,
    2. Schmainda KM
    . Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors. Radiology 2008;249:601–13 doi:10.1148/radiol.2492071659 pmid:18780827
    CrossRefPubMed
  25. 25.↵
    1. Fedorov A,
    2. Beichel R,
    3. Kalpathy-Cramer J, et al
    . 3D Slicer as an image computing platform for the Quantitative Imaging Network. Magn Reson Imaging 2012;30:1323–41 doi:10.1016/j.mri.2012.05.001 pmid:22770690
    CrossRefPubMed
  26. 26.↵
    1. Johnson H,
    2. Harris G,
    3. Williams K
    . BRAINSFit: mutual information rigid registrations of whole-brain 3D images, using the insight toolkit. 2009. https://www.nitrc.org/docman/view.php/52/639/BRAINSFit.pdf. Accessed October 1, 2019
  27. 27.↵
    1. Hu LS,
    2. Baxter LC,
    3. Pinnaduwage DS, et al
    . Optimized preload leakage-correction methods to improve the diagnostic accuracy of dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in posttreatment gliomas. AJNR Am J Neuroradiol 2010;31:40–48 doi:10.3174/ajnr.A1787 pmid:19749223
    Abstract/FREE Full Text
  28. 28.↵
    1. Cha S,
    2. Lupo JM,
    3. Chen MH, et al
    . Differentiation of glioblastoma multiforme and single brain metastasis by peak height and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. AJNR Am J Neuroradiol 2007;28:1078–84 doi:10.3174/ajnr.A0484 pmid:17569962
    Abstract/FREE Full Text
  29. 29.↵
    R Foundation. R: A language and environment for statistical computing. 2020. http://www.r-project.org/. Accessed October 15, 2019
  30. 30.↵
    1. Korfiatis P,
    2. Erickson B
    . The basics of diffusion and perfusion imaging in brain tumors. Appl Radiol 2014;43:22–29 pmid:26456989
    PubMed
  31. 31.↵
    1. Boxerman JL,
    2. Paulson ES,
    3. Prah MA, et al
    . The effect of pulse sequence parameters and contrast agent dose on percentage signal recovery in DSC-MRI: implications for clinical applications. AJNR Am J Neuroradiol 2013;34:1364–69 doi:10.3174/ajnr.A3477 pmid:23413249
    Abstract/FREE Full Text
  32. 32.↵
    1. Qian L,
    2. Tomuleasa C,
    3. Florian I-A, et al
    . Advances in the treatment of newly diagnosed primary central nervous system lymphomas. Blood Res 2017;52:159–66 doi:10.5045/br.2017.52.3.159 pmid:29043230
    CrossRefPubMed
  33. 33.↵
    1. Hoang-Xuan K,
    2. Bessell E,
    3. Bromberg J, et al
    ; European Association for Neuro-Oncology Task Force on Primary CNS Lymphoma. Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. Lancet Oncol 2015;16:e322–32 doi:10.1016/S1470-2045(15)00076-5 pmid:26149884
    CrossRefPubMed
  34. 34.↵
    1. Önder E,
    2. Arıkök AT,
    3. Önder S, et al
    . Corticosteroid pre-treated primary CNS lymphoma: a detailed analysis of stereotactic biopsy findings and consideration of interobserver variability. Int J Clin Exp Pathol 2015;8:7798–808 pmid:26339344
    PubMed
  35. 35.↵
    1. Weller M,
    2. Martus P,
    3. Roth P, et al
    ; German PCNSL Study Group. Surgery for primary CNS lymphoma? Challenging a paradigm. Neuro Oncol 2012;14:1481–84 doi:10.1093/neuonc/nos159 pmid:22984018
    CrossRefPubMed
  • Received May 5, 2020.
  • Accepted after revision July 3, 2020.
  • © 2020 by American Journal of Neuroradiology
View Abstract
PreviousNext
Back to top

In this issue

American Journal of Neuroradiology: 41 (10)
American Journal of Neuroradiology
Vol. 41, Issue 10
1 Oct 2020
  • Table of Contents
  • Index by author
  • Complete Issue (PDF)
Advertisement
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on American Journal of Neuroradiology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Presurgical Identification of Primary Central Nervous System Lymphoma with Normalized Time-Intensity Curve: A Pilot Study of a New Method to Analyze DSC-PWI
(Your Name) has sent you a message from American Journal of Neuroradiology
(Your Name) thought you would like to see the American Journal of Neuroradiology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Cite this article
A. Pons-Escoda, A. Garcia-Ruiz, P. Naval-Baudin, M. Cos, N. Vidal, G. Plans, J. Bruna, R. Perez-Lopez, C. Majos
Presurgical Identification of Primary Central Nervous System Lymphoma with Normalized Time-Intensity Curve: A Pilot Study of a New Method to Analyze DSC-PWI
American Journal of Neuroradiology Oct 2020, 41 (10) 1816-1824; DOI: 10.3174/ajnr.A6761

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
0 Responses
Respond to this article
Share
Bookmark this article
Presurgical Identification of Primary Central Nervous System Lymphoma with Normalized Time-Intensity Curve: A Pilot Study of a New Method to Analyze DSC-PWI
A. Pons-Escoda, A. Garcia-Ruiz, P. Naval-Baudin, M. Cos, N. Vidal, G. Plans, J. Bruna, R. Perez-Lopez, C. Majos
American Journal of Neuroradiology Oct 2020, 41 (10) 1816-1824; DOI: 10.3174/ajnr.A6761
del.icio.us logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Purchase

Jump to section

  • Article
    • Abstract
    • ABBREVIATIONS:
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSIONS
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • Responses
  • References
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • Imaging of Lymphomas Involving the CNS: An Update-Review of the Full Spectrum of Disease with an Emphasis on the World Health Organization Classifications of CNS Tumors 2021 and Hematolymphoid Tumors 2022
  • Diffuse Large B-Cell Epstein-Barr Virus-Positive Primary CNS Lymphoma in Non-AIDS Patients: High Diagnostic Accuracy of DSC Perfusion Metrics
  • Crossref (18)
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Imaging of Lymphomas Involving the CNS: An Update-Review of the Full Spectrum of Disease with an Emphasis on the World Health Organization Classifications of CNS Tumors 2021 and Hematolymphoid Tumors 2022
    A. Pons-Escoda, P. Naval-Baudin, R. Velasco, N. Vidal, C. Majós
    American Journal of Neuroradiology 2023 44 4
  • Voxel-level analysis of normalized DSC-PWI time-intensity curves: a potential generalizable approach and its proof of concept in discriminating glioblastoma and metastasis
    Albert Pons-Escoda, Alonso Garcia-Ruiz, Pablo Naval-Baudin, Francesco Grussu, Juan Jose Sanchez Fernandez, Angels Camins Simo, Noemi Vidal Sarro, Alejandro Fernandez-Coello, Jordi Bruna, Monica Cos, Raquel Perez-Lopez, Carles Majos
    European Radiology 2022 32 6
  • Classifying primary central nervous system lymphoma from glioblastoma using deep learning and radiomics based machine learning approach - a systematic review and meta-analysis
    Amrita Guha, Jayant S. Goda, Archya Dasgupta, Abhishek Mahajan, Soutik Halder, Jeetendra Gawde, Sanjay Talole
    Frontiers in Oncology 2022 12
  • Dynamic-susceptibility-contrast perfusion-weighted-imaging (DSC-PWI) in brain tumors: a brief up-to-date overview for clinical neuroradiologists
    Albert Pons-Escoda, Marion Smits
    European Radiology 2023 33 11
  • Simultaneous quantification of perfusion, permeability, and leakage effects in brain gliomas using dynamic spin-and-gradient-echo echoplanar imaging MRI
    Francesco Sanvito, Catalina Raymond, Nicholas S. Cho, Jingwen Yao, Akifumi Hagiwara, Joey Orpilla, Linda M. Liau, Richard G. Everson, Phioanh L. Nghiemphu, Albert Lai, Robert Prins, Noriko Salamon, Timothy F. Cloughesy, Benjamin M. Ellingson
    European Radiology 2023 34 5
  • Improved performance of non-preloaded and high flip-angle dynamic susceptibility contrast perfusion-weighted imaging sequences in the presurgical differentiation of brain lymphoma and glioblastoma
    Feng Wang, Xiaofang Zhou, Ruiquan Chen, Jie Kang, Xinyi Yang, Jinzhu Lin, Fang Liu, Dairong Cao, Zhen Xing
    European Radiology 2023 33 12
  • Differentiating IDH-mutant astrocytomas and 1p19q-codeleted oligodendrogliomas using DSC-PWI: high performance through cerebral blood volume and percentage of signal recovery percentiles
    Albert Pons-Escoda, Alonso Garcia-Ruiz, Pablo Naval-Baudin, Ignacio Martinez-Zalacain, Josep Castell, Angels Camins, Noemi Vidal, Jordi Bruna, Monica Cos, Raquel Perez-Lopez, Laura Oleaga, Esther Warnert, Marion Smits, Carles Majos
    European Radiology 2024 34 8
  • Diffuse Large B-Cell Epstein-Barr Virus–Positive Primary CNS Lymphoma in Non-AIDS Patients: High Diagnostic Accuracy of DSC Perfusion Metrics
    A. Pons-Escoda, A. García-Ruíz, P. Naval-Baudin, F. Grussu, M. Viveros, N. Vidal, J. Bruna, G. Plans, M. Cos, R. Perez-Lopez, C. Majós
    American Journal of Neuroradiology 2022 43 11
  • MR dynamic-susceptibility-contrast perfusion metrics in the presurgical discrimination of adult solitary intra-axial cerebellar tumors
    Albert Pons-Escoda, Alonso Garcia-Ruiz, Clemente Garcia-Hidalgo, Ruben Gil-Solsona, Pablo Naval-Baudin, Teodoro Martin-Noguerol, Alejandro Fernandez-Coello, Susanie Flores-Casaperalta, Montserrat Fernandez-Viñas, Pablo Gago-Ferrero, Laura Oleaga, Raquel Perez-Lopez, Carles Majos
    European Radiology 2023 33 12
  • Multiparametric Framework Magnetic Resonance Imaging Assessment of Subtypes of Intracranial Germ Cell Tumors Using Susceptibility Weighted Imaging, Diffusion‐Weighted Imaging, and Dynamic Susceptibility‐Contrast Perfusion‐Weighted Imaging Combined With Conventional Magnetic Resonance Imaging
    Yanong Li, Peng Wang, Jing Zhang, Jane Li, Li Chen, Xiaoguang Qiu
    Journal of Magnetic Resonance Imaging 2022 56 4

More in this TOC Section

Adult Brain

  • Diagnostic Neuroradiology of Monoclonal Antibodies
  • ML for Glioma Molecular Subtype Prediction
  • Segmentation of Brain Metastases with BLAST
Show more Adult Brain

Functional

  • Glutaric Aciduria Type 1: DK vs. Conventional MRI
  • Kurtosis and Epileptogenic Tubers: A Pilot Study
  • Choroid Plexus Calcification&Microglial Activation
Show more Functional

Similar Articles

Advertisement

Indexed Content

  • Current Issue
  • Accepted Manuscripts
  • Article Preview
  • Past Issues
  • Editorials
  • Editors Choice
  • Fellow Journal Club
  • Letters to the Editor

Cases

  • Case Collection
  • Archive - Case of the Week
  • Archive - Case of the Month
  • Archive - Classic Case

Special Collections

  • Special Collections

Resources

  • News and Updates
  • Turn around Times
  • Submit a Manuscript
  • Author Policies
  • Manuscript Submission Guidelines
  • Evidence-Based Medicine Level Guide
  • Publishing Checklists
  • Graphical Abstract Preparation
  • Imaging Protocol Submission
  • Submit a Case
  • Become a Reviewer/Academy of Reviewers
  • Get Peer Review Credit from Publons

Multimedia

  • AJNR Podcast
  • AJNR SCANtastic
  • Video Articles

About Us

  • About AJNR
  • Editorial Board
  • Not an AJNR Subscriber? Join Now
  • Alerts
  • Feedback
  • Advertise with us
  • Librarian Resources
  • Permissions
  • Terms and Conditions

American Society of Neuroradiology

  • Not an ASNR Member? Join Now

© 2025 by the American Society of Neuroradiology All rights, including for text and data mining, AI training, and similar technologies, are reserved.
Print ISSN: 0195-6108 Online ISSN: 1936-959X

Powered by HighWire